Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 27, 2026 | BitPath Holdings Launches Gen 2 Digital Asset Treasury Strategy with altFINS Using AI Analytics and Active Management | BitPath's Gen 2 DAT is designed to harness upside from projects at the intersection of blockchain and AI including smart contracts and L1 and L2 networks. BitPath Holdings, Inc. (OTCMKTS:BPTH) The Gen 2 DAT value creation should be material... |
| May 14, 2026 | BIO-PATH ANNOUNCES REPOSITIONING TO SUPPORT GROWTH, ADDS SCIENTIFIC ADVISORS, ENGAGES BANKERS, CANCELS REVERSE SPLIT | An oncology-focused biotechnology company. Turnaround to restart late Phase 2 trial targeting leukemia. Company mulling offers for licenses, partnerships, or sale of intellectual property and assets. Bio-Path Holdings, Inc. (OTCMKTS:BPTH) I... |
| Mar 8, 2024 | Bio-Path Holdings Reports Full Year 2023 Financial Results | |
| Jan 6, 2022 | Bio Path : to Present at H.C. Wainwright BioConnect 2022 Virtual Conference - Form 8-K | Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference HOUSTON - January 5, 2022 - Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticl... |
| Dec 13, 2021 | Bio Path : Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting - Form 8-K | Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients HOUSTON - December ... |
| Dec 13, 2021 | Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting | HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer ... |
| Nov 12, 2021 | Bio-Path Holdings Reports Third Quarter 2021 Financial Results - Form 8-K | Bio-Path Holdings Reports Third Quarter 2021 Financial Results Conference Call to be Held Today at 8:30 A.M. ET HOUSTON-November 12, 2021 - Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize... |
| Oct 27, 2021 | Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors - Form 8-K | Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors Phase 1/1b Clinical Trial to Evaluate Ability of Prexigebersen-A to Treat Patients with Solid Tum... |
| Aug 24, 2021 | Bio Path : Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients (Form 8-K) | Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refr... |
Show more
Reviews 0
FAQ about Bio-Path Holdings, Inc.
What has the press written about Bio-Path Holdings, Inc.?
Parsers VC has collected 14 articles mentioning Bio-Path Holdings, Inc., among them “BitPath Holdings Launches Gen 2 Digital Asset Treasury Strategy with altFINS Using AI Analytics and Active Management” (Aug 27, 2026) and “BIO-PATH ANNOUNCES REPOSITIONING TO SUPPORT GROWTH, ADDS SCIENTIFIC ADVISORS, ENGAGES BANKERS, CANCELS REVERSE SPLIT” (May 14, 2026).
Is Bio-Path Holdings, Inc. still active?
Yes, Bio-Path Holdings, Inc. is active; its latest activity on Parsers VC dates from Sep 4, 2026.